Effect of Lactobacillus casei Shirota on colonic transit time in patients with chronic constipation

Krammer, Heiner; Seggern, H. von; Schaumburg, Joann; Neumer, Franka

doi:10.1007/s00053-011-0177-0

Cited by 49 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 Furthermore, whereas the current study used the internationally accepted Rome III criteria to diagnose chronic constipation, others have used a variation of less stringent definitions for diagnosing constipation, for example, based on stool frequency or WGTT alone. 24,36,37 There are also other factors that could justify the lack of effect seen in the current study. Firstly, this study was not powered for any of the clinical endpoints and, hence, the sample size may have been too small to detect a significant difference in the symptoms and quality of life.…”

Section: Discussionmentioning

confidence: 83%

“…For example, Waller et al , measured weekly stool frequency using a VAS score, instead of completing daily bowel diaries . Furthermore, whereas the current study used the internationally accepted Rome III criteria to diagnose chronic constipation, others have used a variation of less stringent definitions for diagnosing constipation, for example, based on stool frequency or WGTT alone …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Randomised clinical trial: Bifidobacterium lactis NCC2818 probiotic vs placebo, and impact on gut transit time, symptoms, and gut microbiology in chronic constipation

Dimidi

Zdanaviciene

Christodoulides

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Constipation is a prevalent gastrointestinal disorder. Patient dissatisfaction with prescribed medications is common, and there is need for alternative management strategies. Evidence shows that Bifidobacterium species may be beneficial in constipation. Aim To investigate changes in physiological and clinical measures of gut function in patients with chronic constipation following the consumption of Bifidobacterium lactis NCC2818, compared to placebo. Methods Participants were randomised to a 4‐week supplementation with B. lactis NCC2818 (1.5 x 1010 CFU/d) or placebo. Gut transit time was measured using a radio‐opaque marker, while symptoms and quality of life were assessed using validated questionnaires. Gut microbiota composition was assessed using quantitative polymerase chain reaction. Analysis of covariance was used for normally distributed variables, and Mann‐Whitney test for non‐normally distributed variables. Results Seventy‐five participants were randomised. There was no significant difference between the probiotic and placebo groups in gut transit time change from baseline to week 2 (−11.7 hours, SD 33.0 hours vs −12.9 hours, SD 33.6 hours; P = 0.863) or to week 4 (−20.4 hours, SD 32.5 h vs −8.7 hours, SD 33.8 hours; P = 0.103). There were also no improvements in stool output, symptoms, or quality of life. No differences were found in Bifidobacterium concentrations between the probiotic and placebo groups at week 4 (9.5 log10/g dry faeces, SD 0.3 vs 9.4 log10/g, SD 1.0; P = 0.509). Conclusions Bifidobacterium lactis NCC2818 was not effective in the management of mild chronic constipation. This study highlights the importance of further studies and their publication to better understand the strain‐specific effects of probiotics.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Randomised clinical trial: Bifidobacterium lactis NCC2818 probiotic vs placebo, and impact on gut transit time, symptoms, and gut microbiology in chronic constipation

Dimidi

Zdanaviciene

Christodoulides

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Probiotics that increase motility can also have the benefit of reducing constipation; whereas those that decrease motility may reduce diarrhoea (permeability changes are also relevant). Some Lactobacillus, Bifidobacterium and Streptococcus species increase intestinal motility in vitro (Massi et al, 2006;Wang et al, 2010) and in vivo (Ohashi et al, 2001) and reduce transit times from approximately 4 to 3 days in patients with chronic constipation (Krammer et al, 2011).…”

Section: Wwwintechopencommentioning

confidence: 99%

The Role of Intestinal Barrier Function in Early Life in the Development of Colitis

Anderson¹,

Dalziel²,

Gopal³

et al. 2012

Colitis

View full text Add to dashboard Cite

“…described a positive effect in constipated patients (Krammer, Seggern, Schaumburg, & Neumer, 2011;Mazlyn, Nagarajah, Fatimah, Norimah, & Goh, 2013). In gastrectomized patients, these positive effects on constipation and diarrhea were described in a study from Aoki et al where both the symptoms of constipation and diarrhea improved after administration of LcS (Aoki et al, 2014).…”

Section: Bowel Movementsmentioning

confidence: 84%

Probiotic Lactobacillus casei Shirota improves kidney function, inflammation and bowel movements in hospitalized patients with acute gastroenteritis – A prospective study

Akoglu

Loytved

Nuiding

et al. 2015

Journal of Functional Foods

View full text Add to dashboard Cite

Effect of Lactobacillus casei Shirota on colonic transit time in patients with chronic constipation

Cited by 49 publications

References 23 publications

Randomised clinical trial: Bifidobacterium lactis NCC2818 probiotic vs placebo, and impact on gut transit time, symptoms, and gut microbiology in chronic constipation

Randomised clinical trial: Bifidobacterium lactis NCC2818 probiotic vs placebo, and impact on gut transit time, symptoms, and gut microbiology in chronic constipation

The Role of Intestinal Barrier Function in Early Life in the Development of Colitis

Probiotic Lactobacillus casei Shirota improves kidney function, inflammation and bowel movements in hospitalized patients with acute gastroenteritis – A prospective study

Contact Info

Product

Resources

About